Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome

Annals of Hematology

Volumn 92, Issue 12, 2013, Pages 1617-1623

  Zipperer, Esther ^a   Post, Jochen G ^a   Herkert, Matthias ^b   Kündgen, Andrea ^a   Fox, Frank ^a   Haas, Rainer ^a   Gattermann, Norbert ^a   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b DRG Instruments GmbH   (Germany)

Author keywords

Hepcidin; Iron metabolism; Iron overload; Myelodysplastic syndromes (MDS)

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; TRANSFERRIN;

AGED; ARTICLE; BLOOD TRANSFUSION; CHROMOSOME 5Q; CHROMOSOME DELETION; CHRONIC MYELOMONOCYTIC LEUKEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SURVIVAL;

AGED; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPCIDINS; HUMANS; IRON; MALE; MYELODYSPLASTIC SYNDROMES; REGISTRIES; SURVIVAL RATE;

EID: 84888133550     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1839-5     Document Type: Article

References (20)

1. Gattermann N, Rachmilewitz EA (2011) Iron overload in MDS - pathophysiology, diagnosis, and complications. Ann Hematol 90(1):1-10. doi: 10.1007/s00277-010-1091-1
2. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480(2-3):147-150
3. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276(11):7806-7810. doi: 10.1074/jbc.M008922200
4. Ganz T, Nemeth E (2006) Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 290(2):G199-G203. doi: 10.1152/ajpgi.00412.2005
5. Kemna EH, Tjalsma H, Podust VN, Swinkels DW (2007) Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 53(4):620-628. doi: 10.1373/clinchem.2006. 079186
6. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JC, Swinkels DW (2009) Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 94(12):1748-1752. doi: 10.3324/haematol.2009. 010322
7. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101(7):2461-2463. doi: 10.1182/blood-2002-10-3235
8. Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102(3):783-788. doi: 10.1182/blood-2003-03-0672
9. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937-951. doi: 10.1182/blood-2009-03-209262
10. Schwarz P, Strnad P, von Figura G, Janetzko A, Krayenbuhl P, Adler G, Kulaksiz H (2011) A novel monoclonal antibody immunoassay for the detection of human serum hepcidin. J Gastroenterol 46(5):648-656. doi: 10.1007/s00535-010- 0344-z
11. Racchi O, Cangemi G, Montanaro F, Del Corso L, Molinari E, Arboscello EBE, Gatti C, Bruzzone A, Mencoboni M, Ghio R (2011) Serum hepcidin in patients with myelodysplastic syndrome and primary myelofibrosis. Leuk Res 35(S1):S151-S153
12. Malcovati L, Della Porta MG, Laarakkers CM, Galli A, Albertini R, Maffioli M, Am-baglio I, Travaglino E, Invernizzi R, Moratti R, Swinkels DW, Cazzola M (2008) Erythroid activity, transfusion iron overload, and hepcidin levels in patients with myelodysplastic syndrome. Blood 112: 2676a (ASH annual meeting abstracts)
13. Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, Cortelezzi A, Corbella M, Bosi A, Reda G, Olivieri O, Cappellini MD (2011) Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One 6(8):e23109. doi: 10.1371/journal.pone.0023109
14. Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Galli A, Da Via MC, Bono E, Ubezio M, Travaglino E, Albertini R, Campbell PJ, Swinkels DW, Cazzola M (2013) Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica 98(3):420-423. doi: 10.3324/haematol.2012.077446
15. Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, Nemeth E, Rachmilewitz EA (2008) Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 142(4):669-671. doi: 10.1111/j.1365-2141.2008. 07225.x
16. Murphy PT, Mitra S, Gleeson M, Desmond R, Swinkels DW (2009) Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol 144(3):451-452. doi: 10.1111/j.1365-2141.2008.07455.x
17. Huang X, Fung ET, Yip C, Zeleniuch-Jacquotte A (2008) Serum prohepcidin is associated with soluble transferrin receptor-1 but not ferritin in healthy post-menopausal women. Blood Cells Mol Dis 41(3):265-269. doi: 10.1016/j.bcmd.2008.06.009
18. El Husseiny NM, Matter MM, Sabry RM, Amin IS (2010) Serum prohepcidin level in myelodysplasia. Scand J Clin Lab Invest 70(5):343-346. doi: 10.3109/00365513.2010.488700
19. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110(7):1037-1044. doi: 10.1172/JCI15686
20. Ganz T, Nemeth E (2011) The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011:538-542. doi: 10.1182/asheducation-2011.1.538